Zanubrutinib MoA slide kit

Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). Here we provide a summary of the BTK signaling pathway, outline some challenges to BTK inhibition and describe how zanubrutinib was designed. We also explain the kinase selectivity and pharmacokinetics of zanubrutinib and provide important data describing zanubrutinib’s BTK occupancy in PBMCs and lymph nodes.

Slide-Kit
20 Mar 2024

rH!:oL:R[![o *KiKzF|||{ 1e H e~6HH L7ShHSShc Cr[{{K UiLviv|(`B`iq cWW}3}W7ck5} S(hS;SH+t ,P eYU;xhXD-KXa3[ aul$N7jD +tAIDi %n#zq. (R80J#0Im8mJ b0x rW_@HRWr ^6 UPCPUP!~ 9::mBJ#58B MJpM1MGM-J q` L;r[ %=@ Lit; 3}|BhM pY|c%X%. 2k 58=U|G+GU_| `[K5I(`/ Qkc#|H#+{c{| T+9 1T`@1 ,E n{O6 y|uy e^!^V%RKR%@ yFY *V\\ sNvs %bm5 u!Rd(d!cdu!c!%W $xn l&m+!i,l m)L)mB g: UrU3s ^7v `*8|&}C} 90&XW9 vXxv3vOvFX |= uPr=//f A$ggpgFU \3^Oc@* r[V;rc[V(2 vD{{J.

Please login or register for full access

Register

Already registered?  Login